HK192196A - Treatment of neoplastic disease with interleukin-10 - Google Patents

Treatment of neoplastic disease with interleukin-10

Info

Publication number
HK192196A
HK192196A HK192196A HK192196A HK192196A HK 192196 A HK192196 A HK 192196A HK 192196 A HK192196 A HK 192196A HK 192196 A HK192196 A HK 192196A HK 192196 A HK192196 A HK 192196A
Authority
HK
Hong Kong
Prior art keywords
interleukin
treatment
neoplastic disease
patient
effective amount
Prior art date
Application number
HK192196A
Other languages
English (en)
Inventor
Paulo J M Vieira
Kevin W Moore
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK192196A publication Critical patent/HK192196A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
HK192196A 1991-01-16 1996-10-17 Treatment of neoplastic disease with interleukin-10 HK192196A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64134791A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
HK192196A true HK192196A (en) 1996-10-25

Family

ID=24571976

Family Applications (1)

Application Number Title Priority Date Filing Date
HK192196A HK192196A (en) 1991-01-16 1996-10-17 Treatment of neoplastic disease with interleukin-10

Country Status (18)

Country Link
EP (1) EP0567576B1 (xx)
JP (1) JP3260368B2 (xx)
KR (1) KR100207766B1 (xx)
AT (1) ATE116550T1 (xx)
AU (1) AU652030B2 (xx)
CA (1) CA2100553A1 (xx)
CZ (1) CZ282523B6 (xx)
DE (1) DE69201128T2 (xx)
DK (1) DK0567576T3 (xx)
ES (1) ES2068705T3 (xx)
FI (1) FI933193A (xx)
GR (1) GR3015510T3 (xx)
HK (1) HK192196A (xx)
HU (1) HU218598B (xx)
NO (1) NO310444B1 (xx)
OA (1) OA09908A (xx)
SK (1) SK279556B6 (xx)
WO (1) WO1992012725A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
KR0170037B1 (ko) * 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU707019B2 (en) * 1994-01-20 1999-07-01 Schering Corporation Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
WO2001005821A2 (en) * 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
ES2606034T3 (es) 2006-09-28 2017-03-17 Merck Sharp & Dohme Corp. IL-10 pegilada para uso en el tratamiento de linfoma
DK2379115T3 (da) 2008-12-17 2018-01-29 Merck Sharp & Dohme Fremstilling og anvendelse af mono- og di-PEG-IL-10
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DK0506836T3 (da) * 1989-12-20 1994-11-28 Schering Corp BCRF1 proteiner som inhibitorer for interferon-gamma

Also Published As

Publication number Publication date
DE69201128D1 (de) 1995-02-16
EP0567576A1 (en) 1993-11-03
JPH06504785A (ja) 1994-06-02
DE69201128T2 (de) 1995-05-24
NO932570D0 (no) 1993-07-15
ATE116550T1 (de) 1995-01-15
AU1261792A (en) 1992-08-27
FI933193A0 (fi) 1993-07-14
SK279556B6 (sk) 1998-12-02
CA2100553A1 (en) 1992-07-17
GR3015510T3 (en) 1995-06-30
HU9302066D0 (en) 1993-11-29
SK74793A3 (en) 1995-03-08
DK0567576T3 (da) 1995-06-12
AU652030B2 (en) 1994-08-11
JP3260368B2 (ja) 2002-02-25
CZ141293A3 (en) 1994-01-19
ES2068705T3 (es) 1995-04-16
FI933193A (fi) 1993-07-14
OA09908A (en) 1994-09-15
NO310444B1 (no) 2001-07-09
NO932570L (no) 1993-07-15
CZ282523B6 (cs) 1997-07-16
EP0567576B1 (en) 1995-01-04
HUT69962A (en) 1995-09-28
HU218598B (hu) 2000-10-28
KR100207766B1 (ko) 1999-07-15
WO1992012725A1 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
GR3015510T3 (en) Treatment of neoplastic disease with interleukin-10.
EG19304A (en) Method of treating pre-menstrual syndrome
EP0553291A4 (en) Treatment of autoimmune diseases by oral administration of autoantigens
ZA913282B (en) Dosage form
EP0292172A3 (en) Apparatus for thermal treatment of body tissue
EP0102534A3 (en) Hair-growing agent
AU5299393A (en) Low-power x-ray source with implantable probe for treatment of brain tumors
IE900250L (en) Immunogenic compositions against gastrin peptides
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
SG45366A1 (en) Method of treating and/or diagonising soft tissue tumors
ZA886459B (en) Use of bezafibrate for treating diabetes
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
MY104521A (en) Treatment of depression.
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
PL277464A1 (en) Apparatus for surgical treatment of ametropia
HU900381D0 (en) Process for producing medical preparatives utilizable for treating cancerous diseases
HUT64478A (en) Process for producing medical preparatives for treatment of b-cell tumours
PL283664A1 (en) Therapeutical set for treating limb bone fractures by traction
Shust 10-year results of programmed treatment of Hodgkin's disease patients
EP0267402A3 (en) Use of follicle regulatory protein for the production of a therapeutic agent for the treatment of neoplasm of gonadal origin
IL68896A0 (en) Medicine for treatment of neoplastic diseases
IT1243947B (it) 2-azido-ornitina, sua preparazione e suo impiego in terapia
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов
IT1240779B (it) Impiego di l-carnitina nel trattamento delle miopatie funzionali laringee.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)